ADMA BIOLOGICS, INC. current report, 22 June 2018

ADMA Biologics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Form 8-K, dated June 22, 2018, reports on the Annual Meeting of Stockholders held by ADMA Biologics, Inc. on that date. The filing details the results of shareholder votes and a subsequent executive promotion by the Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.

Material Changes and Corporate Actions

  • Shareholder Votes: Stockholders elected three Class II directors (Steven A. Elms, Adam S. Grossman, and Eric I. Richman) and ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the year ending December 31, 2018.
  • Executive Promotion: Immediately following the Annual Meeting, the Board promoted Brian Lenz from Vice President and Chief Financial Officer to Executive Vice President and Chief Financial Officer.
  • Voting Statistics: As of the record date (April 27, 2018), 36,726,084 shares were outstanding. A quorum was established with 33,415,449 shares represented at the meeting.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The document confirms no reportable related party transactions involving the newly promoted officer.

Key Facts for Investor Verification

  • Verify the tenure and background of the newly promoted Executive Vice President and CFO, Brian Lenz, who has been with the company since May 2012.
  • Confirm the voting results for the three Class II directors, noting that all nominees received significant "For" votes (over 27 million each) with minimal "Withheld" votes.
  • Check the ratification vote for CohnReznick LLP, which passed with 33,371,179 votes "For" versus 31,411 "Against."
  • Review the company's upcoming 10-K or 10-Q filings for the financial metrics absent from this governance-focused report.